Microvast Holdings announces departure of chief financial officer
LONDON - Avacta Therapeutics (AIM:AVCT), a developer of peptide drug conjugates for cancer treatment, has postponed the publication of its preliminary results for the year ended December 31, 2024. The new date for the release is set for Monday, June 6, 2025. The delay comes after the company’s auditors requested additional time to complete their audit processes.
The company reassured stakeholders that this rescheduling does not affect its financial standing or cash runway. Avacta’s CEO, Christina Coughlin, and CFO, Brian Hahn, will present the results in a live broadcast to investors at 11:00 BST on the revised date. The event will be accessible through the Investor Meet Company platform, where both current and potential shareholders can register to attend.
Investors interested in participating can sign up at no cost on the Investor Meet Company website and add Avacta Group PLC to their list. Those who are already following Avacta will receive automatic invitations to the presentation. The company has also made provisions for questions to be submitted in advance via the Investor Meet Company dashboard until 09:00 BST on the day of the announcement, as well as during the presentation itself.
Following the announcement, the results presentation will be available on Avacta’s website under the investor resources section.
This update is based on a press release statement from Avacta Group plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.